|
US2631173A
(en)
|
1949-01-04 |
1953-03-10 |
Phillips Petroleum Co |
Production of cyclooctadiene
|
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
IL54795A
(en)
|
1978-05-26 |
1980-10-26 |
Yeda Res & Dev |
Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types
|
|
US4364934A
(en)
|
1979-12-04 |
1982-12-21 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
ATE151467T1
(de)
|
1987-11-30 |
1997-04-15 |
Univ Iowa Res Found |
Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
|
|
WO1989007970A1
(en)
|
1988-03-02 |
1989-09-08 |
Uab Research Foundation |
Reversible mechanochemical engines comprised of bioelastomers capable of modulable inverse temperature transitions for the interconversion of chemical and mechanical work
|
|
JPH03503894A
(ja)
|
1988-03-25 |
1991-08-29 |
ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション |
オリゴヌクレオチド ｎ‐アルキルホスホラミデート
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
WO1991004753A1
(en)
|
1989-10-02 |
1991-04-18 |
Cetus Corporation |
Conjugates of antisense oligonucleotides and therapeutic uses thereof
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
WO1991018913A1
(en)
|
1990-06-07 |
1991-12-12 |
City Of Hope |
Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5683867A
(en)
|
1990-06-11 |
1997-11-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: blended SELEX
|
|
US5864026A
(en)
|
1990-06-11 |
1999-01-26 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
US5789157A
(en)
|
1990-06-11 |
1998-08-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: tissue selex
|
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
ES2259800T3
(es)
|
1990-06-11 |
2006-10-16 |
Gilead Sciences, Inc. |
Procedimientos de uso de ligandos de acido nucleico.
|
|
US5650275A
(en)
|
1990-06-11 |
1997-07-22 |
Nexstar Pharmacueticals Inc |
Target detection method using spectroscopically detectable nucleic acid ligands
|
|
US6365730B1
(en)
|
1990-06-19 |
2002-04-02 |
Gene Shears Pty. Limited |
DNA-Armed ribozymes and minizymes
|
|
DK0585287T3
(da)
|
1990-07-10 |
2000-04-17 |
Cambridge Antibody Tech |
Fremgangsmåde til fremstilling af specifikke bindingsparelementer
|
|
AU651380B2
(en)
|
1990-07-16 |
1994-07-21 |
University Of Medicine And Dentistry Of New Jersey |
Selection of ribozymes that efficiently cleave target RNA
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
ES2061416T3
(es)
|
1990-10-12 |
1997-03-01 |
Max Planck Gesellschaft |
Ribozimas modificadas.
|
|
EP0563251A1
(en)
|
1990-12-20 |
1993-10-06 |
Exxon Chemical Patents Inc. |
Uv/eb curable butyl copolymers for lithographic and corrosion-resistant coating applications
|
|
EP1820858B1
(en)
|
1991-03-01 |
2009-08-12 |
Dyax Corporation |
Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
|
|
ATE414768T1
(de)
|
1991-04-10 |
2008-12-15 |
Scripps Research Inst |
Bibliotheken heterodimerer rezeptoren mittels phagemiden
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US6100099A
(en)
|
1994-09-06 |
2000-08-08 |
Abbott Laboratories |
Test strip having a diagonal array of capture spots
|
|
CA2118508A1
(en)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US5436143A
(en)
|
1992-12-23 |
1995-07-25 |
Hyman; Edward D. |
Method for enzymatic synthesis of oligonucleotides
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
DE733059T1
(de)
|
1993-12-09 |
1997-08-28 |
Univ Jefferson |
Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5650502A
(en)
|
1994-11-09 |
1997-07-22 |
Hybridon, Inc. |
Ribozyme analogs having rigid non-nucleotidic linkers
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US5693773A
(en)
|
1995-06-07 |
1997-12-02 |
Hybridon Incorporated |
Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US6242246B1
(en)
|
1997-12-15 |
2001-06-05 |
Somalogic, Inc. |
Nucleic acid ligand diagnostic Biochip
|
|
US5989823A
(en)
|
1998-09-18 |
1999-11-23 |
Nexstar Pharmaceuticals, Inc. |
Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
ES2234563T5
(es)
|
1999-02-12 |
2018-01-17 |
Daiichi Sankyo Company, Limited |
Nuevos análogos de nucleósidos y oligonucleótidos
|
|
US6136603A
(en)
|
1999-03-26 |
2000-10-24 |
Isis Pharmaceuticals Inc. |
Antisense modulation of interleukin-5 signal transduction
|
|
US6569630B1
(en)
|
1999-07-02 |
2003-05-27 |
Conceptual Mindworks, Inc. |
Methods and compositions for aptamers against anthrax
|
|
WO2001062738A1
(en)
|
2000-02-22 |
2001-08-30 |
Banyu Pharmaceutical Co., Ltd. |
Novel imidazoline compounds
|
|
US6784291B2
(en)
|
2000-05-04 |
2004-08-31 |
Avi Biopharma, Inc. |
Splice-region antisense composition and method
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
JP4828795B2
(ja)
|
2002-03-11 |
2011-11-30 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
硫酸化多糖類の分析
|
|
US7399586B2
(en)
|
2002-05-23 |
2008-07-15 |
Ceptyr, Inc. |
Modulation of biological signal transduction by RNA interference
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
AU2003295600A1
(en)
|
2002-11-14 |
2004-06-15 |
Dharmacon, Inc. |
Functional and hyperfunctional sirna
|
|
WO2004046160A2
(en)
|
2002-11-18 |
2004-06-03 |
Santaris Pharma A/S |
Amino-lna, thio-lna and alpha-l-oxy-ln
|
|
EP2392660A3
(en)
|
2002-11-25 |
2012-03-28 |
Masafumi Matsuo |
ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor
|
|
WO2004058717A1
(en)
|
2002-12-20 |
2004-07-15 |
X-Ceptor Therapeutics, Inc. |
Isoquinolinone derivatives and their use as therapeutic agents
|
|
DK1592793T3
(da)
|
2003-02-10 |
2009-10-26 |
Santaris Pharma As |
Oligomeriske forbindelser for modulation af Survivin ekspression
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
EP1620564A4
(en)
|
2003-04-18 |
2008-03-12 |
Cytovia Inc |
METHOD FOR TREATING DISEASES RESPONSING TO APOPTOSIS INDUCTION AND SCREENING TESTS
|
|
MXPA06000619A
(es)
|
2003-07-15 |
2006-04-11 |
Hybridon Inc |
Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
|
|
GB0407315D0
(en)
|
2003-07-15 |
2004-05-05 |
Cambridge Antibody Tech |
Human antibody molecules
|
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
GB0324854D0
(en)
|
2003-10-24 |
2003-11-26 |
Expresson Biosystems Ltd |
App/ena antisense
|
|
CA2553955C
(en)
|
2004-02-10 |
2012-08-28 |
Zystor Therapeutics, Inc. |
Acid alpha-glucosidase and fragments thereof
|
|
WO2005087217A1
(en)
|
2004-03-05 |
2005-09-22 |
The General Hospital Corporation |
Compositions and methods for modulating interaction between polypeptides
|
|
US20080199960A1
(en)
|
2004-05-13 |
2008-08-21 |
Juliano Rudolph L |
Methods for the Delivery of Oligomeric Compounds
|
|
JP5697297B2
(ja)
|
2004-05-14 |
2015-04-08 |
ロゼッタ ジノミクス リミテッド |
マイクロｎａｓおよびその使用
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
EP2933332A1
(en)
|
2004-06-28 |
2015-10-21 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
USRE48960E1
(en)
|
2004-06-28 |
2022-03-08 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
WO2006022688A1
(en)
|
2004-08-06 |
2006-03-02 |
Applera Corporation |
Diagnosis of pancreatic cancer by using pancreatic targets
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
US7807619B2
(en)
|
2004-11-01 |
2010-10-05 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US8431558B2
(en)
|
2004-11-01 |
2013-04-30 |
The Regents Of The University Of California |
Compositions and methods for modification of biomolecules
|
|
US20120122801A1
(en)
|
2005-01-05 |
2012-05-17 |
Prosensa B.V. |
Mannose-6-phosphate receptor mediated gene transfer into muscle cells
|
|
WO2006091796A2
(en)
|
2005-02-22 |
2006-08-31 |
Acucela, Inc. |
Compositions and methods for diagnosing and treating retinal diseases
|
|
US7736647B2
(en)
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
JP2009511023A
(ja)
|
2005-10-06 |
2009-03-19 |
ユニバーシティー、オブ、デラウェア |
ハンチントン病の治療のためのｇに富むポリヌクレオチド
|
|
JP2007104971A
(ja)
|
2005-10-14 |
2007-04-26 |
New Industry Research Organization |
ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド
|
|
WO2007090071A2
(en)
|
2006-01-27 |
2007-08-09 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
WO2007089612A2
(en)
|
2006-01-30 |
2007-08-09 |
President And Fellows Of Harvard College |
Methods and compositions for treating and preventing bacterial infections
|
|
HUE040490T2
(hu)
|
2006-02-09 |
2019-03-28 |
Genzyme Corp |
Lassú intraventrikuláris szállítás
|
|
DK3438131T3
(da)
|
2006-02-10 |
2022-04-11 |
Life Technologies Corp |
Oligosaccharidmodifikation og mærkning af proteiner
|
|
EP2007888A2
(en)
|
2006-04-03 |
2008-12-31 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
|
US8859752B2
(en)
|
2006-04-18 |
2014-10-14 |
The Trustees Of The University Of Pennsylvania |
SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
|
|
JP2009536222A
(ja)
|
2006-05-05 |
2009-10-08 |
アイシス ファーマシューティカルズ， インコーポレーテッド |
Ｐｃｓｋ９の発現を調節するための化合物および方法
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
US20080081791A1
(en)
|
2006-07-06 |
2008-04-03 |
Weida Huang |
Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
|
|
SI2049664T1
(sl)
|
2006-08-11 |
2012-04-30 |
Prosensa Technologies Bv |
Enojna veriga oligonukleotidov, komplementarna repetitivnim elementom, za zdravljenje genetskih bolezni, povezanih z nestabilnostjo dnk ponovitev
|
|
CA2666191C
(en)
|
2006-10-09 |
2017-07-11 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of pcsk9
|
|
ES2526295T5
(es)
|
2006-10-18 |
2021-05-04 |
Ionis Pharmaceuticals Inc |
Compuestos antisentido
|
|
EP2097095B1
(en)
|
2006-11-29 |
2016-01-27 |
Nationwide Children's Hospital |
Myostatin inhibition for enhancing muscle and/or improving muscle function
|
|
WO2008089403A2
(en)
|
2007-01-18 |
2008-07-24 |
Genzyme Corporation |
Oligosaccharides comprising an aminooxy group and conjugates thereof
|
|
US8318438B2
(en)
|
2007-03-01 |
2012-11-27 |
The United States Of America As Represented By The Secretary Of The Air Force |
Aptamer-based assays
|
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
USRE48468E1
(en)
|
2007-10-26 |
2021-03-16 |
Biomarin Technologies B.V. |
Means and methods for counteracting muscle disorders
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
WO2009075815A1
(en)
|
2007-12-07 |
2009-06-18 |
Duke University |
Immunomodulating gene therapy
|
|
WO2009090182A1
(en)
|
2008-01-14 |
2009-07-23 |
Santaris Pharma A/S |
C4'-substituted - dna nucleotide gapmer oligonucleotides
|
|
CA2717792A1
(en)
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
EP2274423A2
(en)
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
WO2009144481A2
(en)
|
2008-05-30 |
2009-12-03 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
|
ES2535461T3
(es)
|
2008-07-08 |
2015-05-11 |
Duke University |
Método de tratamiento de la enfermedad por almacenamiento de glucógeno
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
BR122020021379B1
(pt)
|
2008-10-24 |
2021-05-11 |
Sarepta Therapeutics, Inc. |
oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
|
|
AU2009310557B2
(en)
|
2008-10-27 |
2014-09-11 |
Academisch Ziekenhuis Leiden |
Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
|
|
CN102369023A
(zh)
|
2008-12-16 |
2012-03-07 |
建新公司 |
寡糖-蛋白缀合物
|
|
WO2010096369A1
(en)
|
2009-02-18 |
2010-08-26 |
Amicus Therapeutics, Inc. |
Mouse model for pompe disease and methods of use thereof
|
|
EP2421971B1
(en)
|
2009-04-24 |
2016-07-06 |
BioMarin Technologies B.V. |
Oligonucleotide comprising an inosine for treating dmd
|
|
JP5931720B2
(ja)
|
2009-05-08 |
2016-06-08 |
クルナ・インコーポレーテッド |
Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
|
|
EP3679942A1
(en)
|
2009-06-17 |
2020-07-15 |
BioMarin Pharmaceutical Inc. |
Formulations for lysosomal enzymes
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
EP2480659A2
(en)
|
2009-09-24 |
2012-08-01 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
EP2490699A1
(en)
|
2009-10-20 |
2012-08-29 |
Santaris Pharma A/S |
Oral delivery of therapeutically effective lna oligonucleotides
|
|
TR201816523T4
(tr)
|
2009-11-12 |
2018-11-21 |
Univ Western Australia |
Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
|
|
WO2011078797A2
(en)
|
2009-12-22 |
2011-06-30 |
Singapore Health Services Pte. Ltd |
Antisense oligonucleotides and uses threreof
|
|
US8734799B2
(en)
|
2010-04-13 |
2014-05-27 |
The Regents Of The University Of California |
Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
|
|
SI2528625T1
(sl)
|
2010-04-15 |
2013-11-29 |
Spirogen Sarl |
Pirolobenzodiazepini in njihovi konjugati
|
|
EP2563753B9
(en)
|
2010-04-27 |
2016-07-06 |
SynAffix B.V. |
Fused cyclooctyne compounds and their use in metal-free click reactions
|
|
KR20200133284A
(ko)
|
2010-05-28 |
2020-11-26 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
RU2012157167A
(ru)
|
2010-07-12 |
2014-08-20 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Полифункциональные антительные конъюгаты
|
|
EP2595663A4
(en)
|
2010-07-19 |
2014-03-05 |
Isis Pharmaceuticals Inc |
MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
|
|
EP3192880B1
(en)
|
2010-08-18 |
2019-10-09 |
Fred Hutchinson Cancer Research Center |
Nucleic acid agents for use in treating facioscapulohumeral dystrophy (fshd)
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
ES2596977T3
(es)
|
2010-09-02 |
2017-01-13 |
Université de Mons |
Agentes útiles en el tratamiento de la distrofia muscular facioescapulohumeral
|
|
CA2818173C
(en)
|
2010-11-30 |
2022-05-03 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
EP2672977A1
(en)
|
2011-02-08 |
2013-12-18 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Antisense oligonucleotides
|
|
AU2012246822B2
(en)
|
2011-04-22 |
2017-05-25 |
Biomarin Technologies B.V. |
New compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1)
|
|
CN107080847A
(zh)
|
2011-06-24 |
2017-08-22 |
森彻斯有限公司 |
细胞外靶向药物缀合物
|
|
EP2736539B1
(en)
*
|
2011-07-25 |
2017-08-23 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
|
US20140242093A1
(en)
|
2011-07-29 |
2014-08-28 |
Fred Hutchinson Cancer Research Center |
Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject
|
|
WO2013036748A1
(en)
|
2011-09-09 |
2013-03-14 |
Berry, Lana, L. |
Bicyclo[6.1.0]non-4-yne reagents for chemical modification of oligonucleotides
|
|
AU2012308320C1
(en)
|
2011-09-14 |
2018-08-23 |
Translate Bio Ma, Inc. |
Multimeric oligonucleotide compounds
|
|
EP2788026A4
(en)
|
2011-12-05 |
2015-08-05 |
Univ Duke |
V1V2 IMMUNOGENIC
|
|
WO2013086207A1
(en)
|
2011-12-06 |
2013-06-13 |
The Ohio State University |
Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease
|
|
CA2861247C
(en)
|
2011-12-28 |
2021-11-16 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acids
|
|
AU2013203422A1
(en)
|
2012-01-06 |
2013-07-18 |
Bioalliance C.V. |
Anti-transferrin receptor antibodies and methods using same
|
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
WO2013120038A2
(en)
|
2012-02-10 |
2013-08-15 |
Regents Of The University Of Minnesota |
Morpholino targeting dux4 for treating fshd
|
|
BR112014020826A8
(pt)
|
2012-02-24 |
2017-09-19 |
Stem Centrx Inc |
Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
|
|
EP3628326B1
(en)
|
2012-03-15 |
2024-02-28 |
Oxyrane UK Limited |
Methods and materials for treatment of pompe's disease
|
|
CA2907072A1
(en)
|
2012-03-16 |
2013-09-19 |
Valerion Therapeutics, Llc |
Antisense conjugates for decreasing expression of dmpk
|
|
LT2841578T
(lt)
|
2012-04-23 |
2017-09-25 |
Biomarin Technologies B.V. |
Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
EP2684892A1
(en)
|
2012-07-13 |
2014-01-15 |
Association Française contre les Myopathies |
Compositions and methods for duchenne muscular dystrophy gene therapy
|
|
US9873739B2
(en)
|
2012-08-01 |
2018-01-23 |
Ikaika Therapeutics, Llc |
Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
EP2900821B1
(en)
|
2012-09-25 |
2020-04-01 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
US9695418B2
(en)
|
2012-10-11 |
2017-07-04 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and uses thereof
|
|
CN105142672B
(zh)
|
2012-10-23 |
2019-04-05 |
西纳福克斯股份有限公司 |
经修饰的抗体、抗体-缀合物及其制备方法
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
CN110218727A
(zh)
|
2013-03-14 |
2019-09-10 |
萨勒普塔医疗公司 |
用于治疗肌营养不良的外显子跳跃组合物
|
|
US20140315977A1
(en)
|
2013-03-14 |
2014-10-23 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
US20140329762A1
(en)
|
2013-03-15 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
EP3594240B1
(en)
|
2013-05-20 |
2023-12-06 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
|
US20160107999A1
(en)
|
2013-05-24 |
2016-04-21 |
Synaffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
WO2014197748A2
(en)
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US20160201064A1
(en)
|
2013-08-16 |
2016-07-14 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin
|
|
CA2921457A1
(en)
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Heterochromatin forming non-coding rnas
|
|
KR20160047567A
(ko)
|
2013-08-28 |
2016-05-02 |
스템센트알엑스 인코포레이티드 |
조작된 항-dll3 접합체 및 사용 방법
|
|
US20160237430A1
(en)
|
2013-09-23 |
2016-08-18 |
President And Fellows Of Harvard College |
Allele-specific rna silencing for the treatment of hypertrophic cardiomyopathy
|
|
US20160235861A1
(en)
|
2013-10-14 |
2016-08-18 |
SynAffix. B.V. |
Glycoengineered antibody, antibody-conjugate and methods for their preparation
|
|
US9987373B2
(en)
|
2013-10-14 |
2018-06-05 |
Synaffix B.V. |
Modified glycoprotein, protein-conjugate and process for the preparation thereof
|
|
EP2862928A1
(en)
|
2013-10-18 |
2015-04-22 |
Université de Strasbourg |
Dynamin 2 inhibitor for the treatment of centronuclear myopathies
|
|
US10004814B2
(en)
|
2013-11-11 |
2018-06-26 |
Sirna Therapeutics, Inc. |
Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
|
|
US10344284B2
(en)
|
2013-11-14 |
2019-07-09 |
Lina A. Shehadeh |
Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
|
|
EP3088518A4
(en)
|
2013-12-25 |
2017-09-20 |
JCR Pharmaceuticals Co., Ltd. |
Novel anti-transferrin receptor antibody that passes through blood-brain barrier
|
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
|
US11168085B2
(en)
|
2014-01-24 |
2021-11-09 |
Synaffix B.V. |
Process for the cycloaddition of a hetero(aryl) 1,3-dipole compound with a (hetero)cycloalkyne
|
|
US10266502B2
(en)
|
2014-01-24 |
2019-04-23 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
AU2015225496A1
(en)
|
2014-03-03 |
2016-10-13 |
Sujata ACHARJEE |
Chimeric dystrophin-VSV-G-protein to treat dystrophinopathies
|
|
DK3118311T3
(en)
|
2014-03-12 |
2019-03-11 |
Nippon Shinyaku Co Ltd |
Antisense nucleic acid
|
|
EP3119909B1
(en)
|
2014-03-18 |
2019-11-13 |
Fred Hutchinson Cancer Research Center |
Dux4-induced gene expression in facioscapulohumeral muscular dystrophy (fshd)
|
|
JP6750148B2
(ja)
|
2014-04-25 |
2020-09-02 |
公益財団法人野口研究所 |
糖鎖切断抗体の製造方法及び均一糖鎖抗体
|
|
CA2946983A1
(en)
|
2014-04-25 |
2015-10-29 |
Yamaha Motor Power Products Kabushiki Kaisha |
Engine
|
|
EP3795687A1
(en)
|
2014-05-23 |
2021-03-24 |
Genzyme Corporation |
Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
|
|
MX373052B
(es)
|
2014-06-17 |
2020-05-11 |
Nippon Shinyaku Co Ltd |
Acidos nucleicos antisentido.
|
|
EP4148138A1
(en)
|
2014-08-04 |
2023-03-15 |
SynAffix B.V. |
Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof
|
|
CA2957618A1
(en)
|
2014-08-04 |
2016-02-11 |
MiRagen Therapeutics, Inc. |
Inhibitors of myh7b and uses thereof
|
|
EP3185889B1
(en)
|
2014-08-11 |
2020-07-15 |
Shire Human Genetic Therapies, Inc. |
Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
CN114540327B
(zh)
|
2014-09-30 |
2026-03-24 |
阿米库斯治疗学公司 |
具有增强的碳水化合物的高强度酸性α-葡糖苷酶
|
|
CN107106701B
(zh)
|
2014-10-03 |
2020-11-06 |
西纳福克斯股份有限公司 |
磺酰胺接头、其缀合物及制备方法
|
|
EP3218411B1
(en)
|
2014-11-14 |
2022-01-12 |
Ossianix, Inc. |
Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
|
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
TN2017000178A1
(en)
|
2014-11-21 |
2018-10-19 |
Merck Sharp & Dohme |
Insulin receptor partial agonists
|
|
US20190002876A1
(en)
|
2014-12-09 |
2019-01-03 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treatment of friedreich's ataxia
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
EP3262056A4
(en)
|
2015-02-27 |
2018-09-19 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
WO2016170186A1
(en)
|
2015-04-23 |
2016-10-27 |
Synaffix B.V. |
PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
|
|
BR112017023862A2
(pt)
|
2015-05-04 |
2018-07-17 |
Cytomx Therapeutics Inc |
anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
|
|
AU2016264471B2
(en)
|
2015-05-19 |
2022-01-27 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
EA039366B1
(ru)
|
2015-06-24 |
2022-01-19 |
Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. |
Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер
|
|
RU2737637C2
(ru)
|
2015-07-22 |
2020-12-01 |
Инатерис |
Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств
|
|
HUE050061T2
(hu)
|
2015-09-15 |
2020-12-28 |
Nippon Shinyaku Co Ltd |
Antiszensz nukleinsav
|
|
WO2017049157A1
(en)
|
2015-09-18 |
2017-03-23 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
US20180237775A1
(en)
|
2015-09-21 |
2018-08-23 |
Association Institut De Myologie |
Antisense oligonucleotides and uses thereof
|
|
WO2017049407A1
(en)
|
2015-09-23 |
2017-03-30 |
UNIVERSITé LAVAL |
Modification of the dystrophin gene and uses thereof
|
|
IL295755A
(en)
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
SG11201802408RA
(en)
|
2015-11-05 |
2018-05-30 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
DK3386534T3
(da)
|
2015-12-08 |
2020-11-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
UA124622C2
(uk)
|
2015-12-18 |
2021-10-20 |
ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. |
Кон'юговані імуноглобуліни з c-кінцевим лізином
|
|
US10874746B2
(en)
|
2016-02-08 |
2020-12-29 |
Synaffix B.V. |
Sulfamide linkers for use in bioconjugates
|
|
EP3416671A4
(en)
|
2016-02-19 |
2019-10-30 |
Genisphere, LLC |
NUCLEIC ACID CARRIER AND THERAPEUTIC METHODS OF USE
|
|
AU2017239641A1
(en)
|
2016-03-30 |
2018-10-18 |
Amicus Therapeutics, Inc. |
Formulations comprising recombinant acid alpha-glucosidase
|
|
CA3019354A1
(en)
|
2016-03-30 |
2017-10-05 |
Amicus Therapeutics, Inc. |
Method for selection of high m6p recombinant proteins
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
CA3019832C
(en)
|
2016-04-02 |
2023-05-09 |
Research Institute At Nationwide Children's Hospital |
Modified u6 promoter system for tissue specific expression
|
|
FR3049951A1
(fr)
|
2016-04-12 |
2017-10-13 |
Univ Rabelais Francois |
Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose
|
|
WO2017184529A1
(en)
|
2016-04-18 |
2017-10-26 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
CN109462995A
(zh)
|
2016-05-04 |
2019-03-12 |
波涛生命科学有限公司 |
生物活性剂的方法和组合物
|
|
EP3922260A3
(en)
|
2016-05-24 |
2022-06-15 |
Merck Sharp & Dohme Corp. |
Insulin receptor partial agonists and glp-1 analogues
|
|
JP2019520339A
(ja)
|
2016-06-03 |
2019-07-18 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド、その組成物および方法
|
|
DK3473270T5
(da)
*
|
2016-06-20 |
2024-09-09 |
Genahead Bio Inc |
Konjugat af antistof-lægemiddel
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
MX2018016253A
(es)
|
2016-07-05 |
2019-09-09 |
Biomarin Tech Bv |
Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
|
|
US20190330626A1
(en)
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
EP3293259A1
(en)
|
2016-09-12 |
2018-03-14 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
WO2018046774A1
(en)
|
2016-09-12 |
2018-03-15 |
Genethon |
Acid-alpha glucosidase variants and uses thereof
|
|
WO2018057575A1
(en)
|
2016-09-21 |
2018-03-29 |
Alnylam Pharmaceuticals, Inc |
Myostatin irna compositions and methods of use thereof
|
|
ES3038159T3
(en)
|
2016-11-16 |
2025-10-09 |
Academisch Ziekenhuis Leiden |
Substances for targeting various selected organs or tissues
|
|
US10947540B2
(en)
|
2016-11-29 |
2021-03-16 |
Association Institut De Myologie |
Allele-specific silencing therapy for Dynamin 2-related diseases
|
|
AU2017364106A1
(en)
|
2016-11-28 |
2019-06-20 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by CRISPR/Cpfl-mediated gene editing
|
|
WO2018107003A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
KR20240006023A
(ko)
|
2016-12-19 |
2024-01-12 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
KR102497564B1
(ko)
|
2016-12-26 |
2023-02-07 |
제이씨알 파마 가부시키가이샤 |
혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
|
|
AU2017386888B2
(en)
|
2016-12-28 |
2024-08-08 |
Jcr Pharmaceuticals Co., Ltd. |
Lyophilized preparation
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
US20190336615A1
(en)
|
2017-01-27 |
2019-11-07 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
DK3635009T3
(da)
|
2017-06-07 |
2026-03-30 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til internalisering af enzymer
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
WO2019060432A2
(en)
|
2017-09-19 |
2019-03-28 |
Children's National Medical Center |
GAPMERS AND METHODS OF USING THE SAME FOR THE TREATMENT OF MUSCLE DYSTROPHY
|
|
MX2020003130A
(es)
|
2017-09-22 |
2020-09-25 |
Avidity Biosciences Inc |
Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos.
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
WO2019067981A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
EP3687547A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
AU2018345772B2
(en)
|
2017-10-02 |
2025-04-17 |
Research Institute At Nationwide Children's Hospital |
MiRNA detargeting system for tissue specific interference
|
|
EP3691657A4
(en)
|
2017-10-04 |
2021-07-21 |
Avidity Biosciences, Inc. |
NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
|
US11555189B2
(en)
|
2017-10-18 |
2023-01-17 |
Sarepta Therapeutics, Inc. |
Antisense oligomer compounds
|
|
EP3707155A2
(en)
|
2017-11-09 |
2020-09-16 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas systems for treatment of dmd
|
|
AU2018378812B2
(en)
|
2017-12-06 |
2025-05-22 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle atrophy and myotonic dystrophy
|
|
EP3720504A1
(en)
|
2017-12-06 |
2020-10-14 |
Synaffix B.V. |
Enediyne conjugates
|
|
US11459564B2
(en)
|
2017-12-21 |
2022-10-04 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
EP3735252A4
(en)
|
2018-01-04 |
2021-10-06 |
Avidity Biosciences, Inc. |
HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
AU2019216321A1
(en)
|
2018-01-31 |
2020-07-30 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for correcting dystrophin mutations in human cardiomyocytes
|
|
US12458668B2
(en)
|
2018-02-02 |
2025-11-04 |
Fred Hutchinson Cancer Center |
Methods for treating facioscapulohumeral muscular dystrophy
|
|
IL276327B2
(en)
|
2018-02-05 |
2024-05-01 |
Japan Chem Res |
Method for delivering drug to muscle
|
|
US12258597B2
(en)
|
2018-02-07 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for therapeutic protein delivery
|
|
SG11202009877XA
(en)
|
2018-04-12 |
2020-11-27 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods of use thereof
|
|
JP2021521794A
(ja)
|
2018-04-26 |
2021-08-30 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
JP7665509B2
(ja)
|
2018-05-11 |
2025-04-21 |
アルファ アノマリック エスアエス |
７’－５’－アルファ－アノマー二環式糖ヌクレオシドを含むオリゴヌクレオチドコンジュゲート
|
|
US12391942B2
(en)
|
2018-05-11 |
2025-08-19 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
WO2019241385A2
(en)
|
2018-06-13 |
2019-12-19 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystropy
|
|
EP3810775A1
(en)
|
2018-06-21 |
2021-04-28 |
The Board Of Regents Of The University Of Texas System |
Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy
|
|
AU2019314538B2
(en)
|
2018-08-02 |
2025-03-13 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP3829645A4
(en)
|
2018-08-02 |
2022-05-18 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF PROGRESSIVE FIBRODYSPLASIA OSSIFIANS
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
KR20210086601A
(ko)
|
2018-08-02 |
2021-07-08 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 프리드라이히 운동실조를 치료하기 위한 그의 용도
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2020028836A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
SG11202100928QA
(en)
|
2018-08-02 |
2021-02-25 |
Dyne Therapeutics Inc |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
WO2020028842A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy
|
|
EP3830130A4
(en)
|
2018-08-02 |
2022-05-18 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating centronuclear myopathy
|
|
US20210317226A1
(en)
|
2018-08-02 |
2021-10-14 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
IL280536B2
(en)
|
2018-08-02 |
2024-12-01 |
Dyne Therapeutics Inc |
Complexes targeting transferrin receptor and uses thereof
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
US11708569B2
(en)
|
2018-08-29 |
2023-07-25 |
University Of Copenhagen |
Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid
|
|
IT201800009682A1
(it)
|
2018-10-22 |
2020-04-22 |
Ice Spa |
Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive
|
|
CN113260384A
(zh)
|
2018-11-05 |
2021-08-13 |
西纳福克斯股份有限公司 |
用于靶向表达trop-2的肿瘤的抗体缀合物
|
|
JP2022513719A
(ja)
|
2018-12-06 |
2022-02-09 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
IL312067B2
(en)
|
2018-12-21 |
2025-08-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and uses thereof
|
|
EP3906308A1
(en)
|
2018-12-31 |
2021-11-10 |
Research Institute at Nationwide Children's Hospital |
Dux4 rna silencing using rna targeting crispr-cas13b
|
|
US20220152086A1
(en)
|
2019-03-28 |
2022-05-19 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy with casimersen
|
|
CN113677374A
(zh)
|
2019-04-08 |
2021-11-19 |
国立大学法人东京医科齿科大学 |
肌疾病治疗用药物组合物
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
WO2020219820A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
CN114375296A
(zh)
|
2019-06-06 |
2022-04-19 |
艾维迪提生物科学公司 |
核酸多肽组合物及其用途
|
|
US12006499B2
(en)
|
2019-06-06 |
2024-06-11 |
Avidity Biosciences, Inc. |
Una amidites and uses thereof
|
|
CN119874910A
(zh)
|
2019-06-07 |
2025-04-25 |
达因疗法公司 |
制备蛋白质-寡核苷酸复合物的方法
|
|
JP2022536495A
(ja)
|
2019-06-19 |
2022-08-17 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療する方法
|
|
EP3997228A4
(en)
|
2019-07-09 |
2024-05-15 |
The Governors of the University of Alberta |
SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE
|
|
US20240148891A1
(en)
|
2019-10-18 |
2024-05-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
CA3166370A1
(en)
|
2019-11-27 |
2021-06-03 |
Dtx Pharma, Inc. |
Compounds and methods for the treatment of duchenne muscular dystrophy
|
|
JP2023507575A
(ja)
|
2019-12-20 |
2023-02-24 |
コデクシス， インコーポレイテッド |
操作された酸性アルファ－グルコシダーゼバリアント
|
|
WO2021142260A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of acvr1
|
|
JP7780691B2
(ja)
|
2020-01-10 |
2025-12-05 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用
|
|
WO2021142217A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Thereapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of milck1
|
|
AU2021206234A1
(en)
|
2020-01-10 |
2022-09-01 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
WO2021142269A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
|
|
KR20220125801A
(ko)
|
2020-01-10 |
2022-09-14 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
US20230203180A1
(en)
|
2020-01-10 |
2023-06-29 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
WO2021142331A1
(en)
|
2020-01-10 |
2021-07-15 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
|
|
CA3163608A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle-targeting complexes and uses thereof
|
|
CA3163283A1
(en)
|
2020-01-10 |
2021-07-15 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
US20230117883A1
(en)
|
2020-01-24 |
2023-04-20 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes and uses thereof in treating muscle atrophy
|
|
US20230103793A1
(en)
|
2020-01-31 |
2023-04-06 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (tfr) antibody and uses thereof
|
|
CN115427059A
(zh)
|
2020-01-31 |
2022-12-02 |
达因疗法公司 |
抗转铁蛋白受体（tfr）抗体及其用途
|
|
WO2021188390A1
(en)
|
2020-03-19 |
2021-09-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
|
SI4126066T1
(sl)
|
2020-03-27 |
2026-04-30 |
Avidity Biosciences, Inc. |
Sestavki in postopki zdravljenja mišične distrofije
|
|
WO2021226107A1
(en)
|
2020-05-05 |
2021-11-11 |
Avidity Biosciences, Inc. |
Compositions and methods of treating pompe disease
|
|
MX2023000984A
(es)
|
2020-07-23 |
2023-05-03 |
Dyne Therapeutics Inc |
Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias.
|
|
KR20230041760A
(ko)
|
2020-07-23 |
2023-03-24 |
다인 세라퓨틱스, 인크. |
항-트랜스페린 수용체 (tfr) 항체 및 그의 용도
|
|
JP2023535078A
(ja)
|
2020-07-23 |
2023-08-15 |
ダイン セラピューティクス，インコーポレーテッド |
筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用
|
|
EP4185320A4
(en)
|
2020-07-23 |
2025-10-08 |
Dyne Therapeutics Inc |
MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
|
|
KR20230046297A
(ko)
|
2020-07-23 |
2023-04-05 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
|
|
CN116194470B
(zh)
|
2020-07-23 |
2025-10-03 |
达因疗法公司 |
肌肉靶向复合物及其用途
|
|
CA3189861A1
(en)
|
2020-09-01 |
2022-03-10 |
Sean Christopher DAUGHERTY |
Dux4 inhibitors and methods of use thereof
|
|
EP4208173A4
(en)
|
2020-09-03 |
2025-11-26 |
Dyne Therapeutics Inc |
PROCESSES FOR PREPARING PROTEIN-OLIGONUCLEOTIC COMPLEXES
|
|
CA3189065A1
(en)
|
2020-09-11 |
2022-03-17 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
|
|
IL303230A
(en)
|
2020-11-30 |
2023-07-01 |
Res Inst Nationwide Childrens Hospital |
Compositions and methods for treating facioscapulohumeral muscular dystrophy (fshd)
|
|
IL303332A
(en)
|
2020-12-04 |
2023-07-01 |
Dyne Therapeutics Inc |
Antibody-oligonucleotide complexes and their uses
|
|
CA3202832A1
(en)
|
2020-12-31 |
2022-07-07 |
Romesh R. Subramanian |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
EP4271478A4
(en)
|
2020-12-31 |
2025-03-26 |
Dyne Therapeutics, Inc. |
MUSCLE TARGETING COMPLEXES AND THEIR USES FOR TREATING FACIOSCAPULOHUMERAL MYOPATHY
|
|
US20240336915A1
(en)
|
2021-01-22 |
2024-10-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing dux4 expression
|
|
EP4314016A1
(en)
|
2021-03-31 |
2024-02-07 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
|
EP4314298A1
(en)
|
2021-04-02 |
2024-02-07 |
Avidity Biosciences, Inc. |
Antibody-oligonucleotide conjugate and antibody-peptide-oligonucleotide conjugate compositions and methods of inducing exon skipping
|
|
WO2022217366A1
(en)
|
2021-04-14 |
2022-10-20 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Modified oligonucleotides for the treatment of duchenne muscular dystrophy
|
|
IL307937A
(en)
|
2021-04-30 |
2023-12-01 |
Sarepta Therapeutics Inc |
Treatment methods for muscular dystrophy
|
|
US20240294921A1
(en)
|
2021-06-21 |
2024-09-05 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating pompe disease
|
|
CN118251238A
(zh)
|
2021-06-21 |
2024-06-25 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗弗里德赖希共济失调的用途
|
|
WO2022270585A1
(ja)
|
2021-06-23 |
2022-12-29 |
日本新薬株式会社 |
アンチセンスオリゴマーの組み合わせ
|
|
KR20240035823A
(ko)
|
2021-07-09 |
2024-03-18 |
다인 세라퓨틱스, 인크. |
근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
|
|
US20240382513A1
(en)
|
2021-07-09 |
2024-11-21 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
|
|
AU2022309238A1
(en)
|
2021-07-09 |
2024-01-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US11672872B2
(en)
|
2021-07-09 |
2023-06-13 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor antibody and uses thereof
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
JP2024525611A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
JP2024525612A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
JP2024527362A
(ja)
|
2021-07-09 |
2024-07-24 |
ダイン セラピューティクス，インコーポレーテッド |
筋標的化複合体およびジストロフィノパチーを処置するためのその使用
|
|
WO2023283629A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2024525608A
(ja)
|
2021-07-09 |
2024-07-12 |
ダイン セラピューティクス，インコーポレーテッド |
ジストロフィン異常症を処置するための筋標的化複合体および製剤
|
|
CA3226301A1
(en)
|
2021-07-09 |
2023-01-12 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
JPWO2023022229A1
(enExample)
|
2021-08-19 |
2023-02-23 |
|
|
|
US20240390508A1
(en)
|
2021-08-21 |
2024-11-28 |
Takeda Pharmaceutical Company Limited |
Human transferrin receptor binding peptide-drug conjugate
|
|
IL311138A
(en)
|
2021-09-01 |
2024-04-01 |
Entrada Therapeutics Inc |
Compositions and methods for skipping exon 45 in Duchenne muscular dystrophy
|
|
CN118265544A
(zh)
|
2021-09-16 |
2024-06-28 |
艾维迪提生物科学公司 |
治疗面肩肱型肌营养不良的组合物和方法
|
|
EP4401777A4
(en)
|
2021-09-16 |
2025-08-13 |
Dyne Therapeutics Inc |
DOSAGE OF MUSCLE-TARGETING COMPLEXES TO TREAT DYSTROPHINOPATHIES
|
|
AU2022377070A1
(en)
|
2021-11-01 |
2024-04-11 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating dystrophinopathies
|
|
WO2023086864A1
(en)
|
2021-11-12 |
2023-05-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
|
|
JP2025500481A
(ja)
|
2021-12-22 |
2025-01-09 |
サプリーム テクノロジーズ，ベー．フェー． |
筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物
|
|
US20250057971A1
(en)
|
2021-12-22 |
2025-02-20 |
Sapreme Technologies B.V. |
Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders
|
|
WO2023121444A1
(en)
|
2021-12-22 |
2023-06-29 |
Sapreme Technologies B.V. |
Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders
|
|
CA3243078A1
(en)
|
2022-01-27 |
2023-08-03 |
The Governors Of The University Of Alberta |
Antisense therapeutic products conjugate to pre-MIARN splicing modulating peptides for the treatment of diseases
|
|
WO2023154807A2
(en)
|
2022-02-09 |
2023-08-17 |
Locanabio, Inc. |
Compositions and methods for modulating pre-mrna splicing
|
|
WO2023168427A1
(en)
|
2022-03-03 |
2023-09-07 |
Yale University |
Compositions and methods for delivering therapeutic polynucleotides for exon skipping
|
|
JP2025079347A
(ja)
|
2022-03-11 |
2025-05-22 |
日本新薬株式会社 |
キャリアペプチドが連結された核酸
|
|
CN119013401A
(zh)
|
2022-03-17 |
2024-11-22 |
萨勒普塔医疗公司 |
二氨基磷酸酯吗啉代寡聚物缀合物
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
CN119256008A
(zh)
|
2022-04-15 |
2025-01-03 |
达因疗法公司 |
用于治疗强直性肌营养不良的肌肉靶向复合物及其用途
|
|
KR20250004771A
(ko)
|
2022-04-15 |
2025-01-08 |
다인 세라퓨틱스, 인크. |
근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체의 투여
|
|
WO2023201318A1
(en)
|
2022-04-15 |
2023-10-19 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
EP4551230A2
(en)
|
2022-07-06 |
2025-05-14 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
JP2025522877A
(ja)
|
2022-07-06 |
2025-07-17 |
ダイン セラピューティクス，インコーポレーテッド |
Ｃｎｓ標的化複合体およびその使用
|
|
JP2025533454A
(ja)
|
2022-09-21 |
2025-10-07 |
サレプタ セラピューティクス， インコーポレイテッド |
Ｄｍｄアンチセンスオリゴヌクレオチド介在性エクソンスキッピング効率
|
|
EP4612185A1
(en)
|
2022-10-31 |
2025-09-10 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene
|
|
KR20250116673A
(ko)
|
2022-11-21 |
2025-08-01 |
펩젠 인크. |
세포-침투 펩티드, 그의 접합체 및 그의 사용 방법
|
|
IL321969A
(en)
|
2023-01-10 |
2025-09-01 |
Ausperbio Therapeutics Inc |
Multi-stranded antisense oligonucleotides modified for use
|
|
WO2024182358A1
(en)
|
2023-02-27 |
2024-09-06 |
Dyne Therapeutics, Inc. |
Methods and compositions for inhibiting progression of intramuscular fibrosis
|